Jonathan B. McHugh

Jonathan B. McHugh

Auto-generated profile, based on publicly available information

Jonathan B. McHugh

Department of Pathology University of Michigan‐Michigan Medicine Ann Arbor Michigan USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2011 in Otolaryngology–Head and Neck Surgery
Verified
Journal Article
Closed access
MNMarc E. Nelson
Marc E. Nelson
TGT. J. Gernon
T. J. Gernon
JTJoseph C. Taylor
Joseph C. Taylor
JMJonathan B. McHugh
Jonathan B. McHugh
MTMarc C. Thorne
Marc C. Thorne

1 June 2013 in JAMA Otolaryngology–Head & Neck Surgery
Verified
Journal Article
Closed access
PDF file
AMAndrew S. McDaniel
Andrew S. McDaniel
SBSarah J. Burgin
Sarah J. Burgin
CBCarol R. Bradford
Carol R. Bradford
JMJonathan B. McHugh
Jonathan B. McHugh
Case report from JAMA Otolaryngology–Head & Neck Surgery — Pathology Quiz Case 2

4 June 2008 in Diagnostic Cytopathology
Verified
Journal Article
Closed access
PDF file
XJXin Jing
Xin Jing
JMJonathan B. McHugh
Jonathan B. McHugh
RPRobert T. Pu
Robert T. Pu

22 March 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
PSPaul L. Swiecicki
Paul L. Swiecicki
EBEmily Bellile
Emily Bellile
ADAleksandar F. Dragovic
Aleksandar F. Dragovic
JMJonathan McHugh
Jonathan McHugh
AUAaron Udager
Aaron Udager
MSMatthew E. Spector
Matthew E. Spector
Purpose: Locoregionally advanced HPV+ oropharyngeal squamous cell carcinoma (OPSCC) has excellent cure rates, although current treatment regimens are accompanied by acute and long-term toxicities. We designed a phase II deescalation trial for patients with HPV+ OPSCC to evaluate the feasibility of an upfront neck dissection to individualize definitive treatment selection to improve the quality of life without compromising survival. Patients and Methods: Patients with T1–3, N0–2 HPV+ OPSCC underwent an upfront neck dissection with primary tumor biopsy. Arm A included patients with a single lymph node less than six centimeters, with no extracapsular spread (ECS) and no primary site adverse features underwent transoral surgery. Arm B included patients who had two or more positive lymph nodes with no ECS, or those with primary site adverse features were treated with radiation alone. Arm C included patients who had ECS in any lymph node and were treated with chemoradiation. The primary endpoint was quality of life at 1 year compared with a matched historical control. Results: Thirty-four patients were enrolled and underwent selective neck dissection. On the basis of pathologic characteristics, 14 patients were assigned to arm A, 10 patients to arm B, and 9 to arm C. A significant improvement was observed in Head and Neck Quality of Life (HNQOL) compared with historical controls (−2.6 vs. −11.9, P = 0.034). With a median follow-up of 37 months, the 3-year overall survival was 100% and estimated 3-year estimated progression-free survival was 96% [95% confidence interval (CI), 76%–99%]. Conclusions: A neck dissection–driven treatment paradigm warrants further research as a deintensification strategy.

1 September 2013 in Journal of Oral and Maxillofacial Surgery
Verified
Journal Article
Closed access
JDJ. Dashow
J. Dashow
JHJ.I. Helman
J.I. Helman
SES.P. Edwards
S.P. Edwards
JMJ. McHugh
J. McHugh
BWB.B. Ward
B.B. Ward

3 April 2023
Verified
Other
Open access
LVLorena Lazo de la Vega
Lorena Lazo de la Vega
JMJonathan B. McHugh
Jonathan B. McHugh
ACAndi Cani
Andi Cani
KKKomal Kunder
Komal Kunder
FWFrances M. Walocko
Frances M. Walocko
PHPaul Harms
Paul Harms
Figure S1. (A) Overexpression of p53 in olfactory neuroblastoma tumor harboring an inactivating TP53 mutation. (B) Representative example of p53 expression in olfactory neuroblastoma tumor lacking TP53 mutation. Immunohistochemistry, 400x magnification. figure S2. (A) Nuclear localization of beta catenin in olfactory neuroblastoma tumor harboring an activating CTNNB1 mutation. (B) Representative example of membranous beta catenin expression in olfactory neuroblastoma tumor lacking CTNNB1 mutation. Immunohistochemistry, 400x magnification. Table S1: Immunohistochemistry protocols Table S2: Clinicopathologic features of olfactory neuroblastoma cohort Table S3: DNA sequencing statistics for profiled olfactory neuroblastoma samples Table S4: Prioritized somatic nonsynonymous mutations in olfactory neuroblastoma cases identified by next generation sequencing Table S5: FGFR3 copy number in olfactory neuroblastomas by next generation sequencing Table S6. Targeted multiplexed PCR based RNA sequencing statistics for ONB samples